Placebo matching BI 764198

DRUG3 trials

Sponsors

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A., Boehringer Ingelheim

Conditions

Focal segmental glomerulosclerosisProteinuric Kidney DiseasesProteinuric kidney diseases

Phase 2

PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease

RecruitingNCT07355296

Boehringer IngelheimProteinuric Kidney Diseases

Start: 2026-03-23End: 2028-02-17Target: 132Updated: 2026-09-16

PODOMOUNT-Basket, a Phase II, multicentre, randomised, 2-arm parallel-group, double-blind, placebo-controlled basket trial to assess safety, tolerability, PK, and efficacy of BI 764198 in four proteinuric kidney diseases

Not yet recruitingCTIS2025-523425-17-00

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.Proteinuric kidney diseases

Target: 20Updated: 2026-05-20

Phase 3

A multicentre, randomised, double-blind, parallel group, placebo-controlled trial to assess the effects of oral TRPC6 inhibitor BI 764198 taken over a 104 week treatment period in adult and adolescent participants with primary focal segmental glomerulosclerosis (pFSGS) or genetic FSGS related to TRPC6 gene variants

Not yet recruitingCTIS2025-522191-86-00

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.Focal segmental glomerulosclerosis

Target: 38Updated: 2026-03-18